ArticleTumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine2015
CC-chemokine receptor 7 is overexpressed and correlates with growth and metastasis in prostate cancer.
Article in Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 9 citations in OpenAlex.
- Article
- Whole blood defensin mRNA expression is a predictive biomarker of docetaxel response in castration-resistant prostate cancer.OncoTargets and therapy · 2015Article
Corrections and comments
- Retraction · 2017-04-20Compromised Peer Review · Investigation by Journal/Publisher · · Journal published by SAGE starting in 2017
- Retracted
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multiple studies have shown that CC-chemokine receptor 7 (CCR7) promotes cell proliferation in several human cancers. We investigated the expression and clinical significance of CCR7 in our large collection of prostate cancer (PCa) samples and explored its function on the proliferation and migration of PCa cells. In this study, the expression of CCR7 was examined by immunohistochemical staining and quantitative RT-PCR in primary PCa tissues from 60 patients who underwent radical prostatectomy. Then, we investigated the functional role of CCR7 in PCa cell proliferation and migration by small interfering RNA-mediated depletion. The positive rate of CCR7 staining was 88.33 % (53/60) in the PCa group and 16.67 % (10/60) in cases of benign prostate hyperplasia (BPH); the difference of CCR7 expression between PCa and BPH was statistically significant. The results were confirmed by quantitative real-time PCR. CCR7 was significantly elevated in all five PCa cell lines when compared to the RWPE-1 cells. Silencing of CCR7 inhibited the proliferation of PC3 cells which have a relatively high level of CCR7 in a time-dependent manner, and the invasion and migration of PC3 cells were distinctly suppressed. Our data suggest that the pathogenesis of human PCa maybe mediated by the CCR7, and thus CCR7 could represent selective targets for the molecularly targeted treatments of PCa.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.